Research progress in targeted immunotherapy combined with ra-diotherapy for stageⅢ/Ⅳmelanomas / 中国肿瘤临床
Chinese Journal of Clinical Oncology
; (24): 255-258, 2015.
Article
en Zh
| WPRIM
| ID: wpr-474869
Biblioteca responsable:
WPRO
ABSTRACT
Melanoma is the most aggressive and lethal malignant tumor in skin cancers. Operation resection is used to treat stageⅠ/Ⅱmelanomas, but traditional operation, chemotherapy, and radiotherapy inflicts adverse effects on late-stage melanomas. StageⅢ/Ⅳmelanomas are some of the most ineffectively treated tumors with poor prognosis. As a cancer treatment, targeted immunotherapy in-hibits negative regulatory factors and enhances systemic anti-tumor immune effects. Radiotherapy not only kills tumor cells, but also en-hances systemic immune responses. Recent studies showed that targeted immunotherapy combined with radiotherapy can promote con-trol on local and distant tumors and prolong overall survival. The synergistic effects of these two therapies are superior to a single thera-py. This review summarized the progress on these research fields.
Texto completo:
1
Índice:
WPRIM
Tipo de estudio:
Prognostic_studies
Idioma:
Zh
Revista:
Chinese Journal of Clinical Oncology
Año:
2015
Tipo del documento:
Article